A phase II trial to evaluate safety and efficacy of adding durvalumab (MEDI4736) to standard neoadjuvant radiochemotherapy and of adjuvant durvalumab +/- tremelimumab in locally advanced esophageal adenocarcinoma and to evaluate biomarkers predictive for response to immune checkpoint inhibition

Authors
Category Primary study
Registry of TrialsEU Clinical Trials Register
Year 2019
This article has no abstract
Epistemonikos ID: b84868aaab18cfe71350fc278ca40c72613c6382
First added on: Jan 23, 2025